TALPHERA, INC.
TLPH · XNASCIK 1427925fmd_1M6RV48X4VP10BG3P0WYME0ENNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2005 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 17 | 8 | 2 | 2 | 5 | 0 | 0 | 1 | 0 | 0 |
| Cost of revenue | 12 | 11 | 4 | 7 | 6 | 1 | 0 | – | – | – |
| Gross profit | 5 | (3) | (2) | (5) | (1) | (0) | 0 | – | – | – |
| Research and development | 21 | 19 | 13 | 5 | 4 | 2 | 3 | 6 | 7 | 6 |
| Selling, general and administrative | – | 17 | 21 | 45 | 36 | 15 | 17 | 12 | 9 | 7 |
| Total operating expenses | 49 | 47 | 38 | – | – | – | – | – | – | – |
| Compensation and benefits | – | – | – | – | – | – | – | 7 | 6 | 6 |
| Operating income | (32) | (39) | (36) | (54) | (41) | (18) | (25) | (17) | (15) | (13) |
| Interest expense | 3 | 3 | 2 | 3 | 3 | 2 | 1 | 0 | 0 | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (11) | (14) | (11) | 1 | 1 | 1 | 84 | 7 | 2 | (1) |
| Income before taxes | (43) | (52) | (47) | (53) | (40) | (17) | 59 | (10) | – | – |
| Income tax expense | (0) | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (43) | (52) | (47) | (53) | (40) | (17) | 59 | (10) | (13) | (14) |
| Net income | (43) | (52) | (47) | (53) | (40) | (35) | 48 | (18) | (13) | (14) |
| Net income to common shareholders | (43) | (52) | – | – | – | (35) | 42 | (18) | – | – |